HOME>Investor Relations

Investor Relations

What's New

  • RSS
  • About RSS

News Release List

2017
December 13 Release Strategic Collaboration for the Development of the Antibody Drug to Treat Neurodegenerative Diseases including ALSPDF NEW
December 5 Topics Business Briefing [Material][Video]
December 1 Topics CSR Information updated
November 22 Release Launch of Rupafin tablets in Japan ―Allergy treatment agent with new mechanism of action shows strong effectiveness with dual action (anti-PAF and antihistamine action)PDF
November 8 Release Distribution Agreement for Clenafin/Jublia in TaiwanPDF
November 1 Topics IR Meeting for FY2017 2nd Quarter Business Results[Material][Audio]
November 1 Release Announcement of FY2017 2nd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
November 1 Release Notice Regarding Mitsubishi Tanabe Pharma’s Acquisition of Stelic Institute & Co., Inc. Securing Nucleic Acid Pharmaceuticals of Inflammatory bowel disease for Future Launch in the U.S.PDF
November 1 Release Notice of the Start of Japanese Phase 3 Clinical Studies of the HIF-PH Inhibitor MT-6548 in Renal AnemiaPDF
October 24 Release Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2018PDF
October 18 Release Completion of Acquisition of NeuroDerm (100% Ownership)PDF
October 11 Release Astellas, Mitsubishi Tanabe Pharma, and Daiichi Sankyo Conduct “JOINUS,” a New Drug Discovery Program Using Drug-Repositioning Compound Library -Three Japanese pharmaceutical companies collaborate in facilitating drug discovery in Japan through open innovation sharing of compounds developed by the companies-PDF
October 2 Release Completion of Transfer of Shares of Generic Drugs Subsidiary (Update of Previous Disclosure)PDF
September 29 Release Organizational Change and Personnel ChangePDF
September 27 Release Notice regarding acquisition of manufacturing and sales approval for Rupafin tablets Allergy treatment agent with new mechanism of action shows strong effectiveness with dual action (anti-PAF and antihistamine action)PDF
September 27 Release Notice of the Start of Phase 3 Clinical Study of VLP Seasonal Influenza VaccinePDF
September 27 Topics R&D Meeting [Material]
September 22 Topics Mitsubishi Tanabe Pharma Corporate Report 2017
September 13 Release Approval of Mitsubishi Tanabe Pharma’s Acquisition of NeuroDerm at NeuroDerm’s General Meeting of ShareholdersPDF
September 7 Release Japan’s First DPP-4 Inhibitor / SGLT2 Inhibitor Combination Drug Launch of CANALIA Combination Tablets, a type 2 diabetes mellitus treatment agent-Combination of selective DPP-4 inhibitor TENELIA Tablets and SGLT2 inhibitor CANAGLU Tablets-PDF
September 4 Release Start of Operations of Vaccine Manufacturing Joint Venture: BIKEN Co., Ltd.PDF
August 17 Release Notice of the Start of a Japanese Phase 2/3 Clinical Study of the Anti-NGF Antibody MT-5547 in OsteoarthritisPDF
August 9 Topics RADICAVA to treat ALS now available in U.S.
July 31 Topics IR Meeting for FY2017 1st Quarter Business Results[Material][Audio]
July 31 Release Announcement of FY2017 1st Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
July 27 Release Notice regarding the initiation of a phase 2/3 clinical trial in Japan for tardive dyskinesia patients for VMAT2 inhibitor MT-5199PDF
July 24 Topics Analysts meeting on acquisition of NeuroDerm [Material][Audio]
July 24 Release Mitsubishi Tanabe Pharma to Acquire NeuroDerm Ltd.PDF
July 3 Release Japan’s First DPP-4 Inhibitor / SGLT2 Inhibitor Combination Drug ―Application approved in Japan for CANALIA Combination Tablets, a type 2 diabetes mellitus treatment agent -Combination of selective DPP-4 inhibitor TENELIA Tablets and SGLT2 inhibitor CANAGLU Tablets-PDF
June 30 Release Conclusion of Agreement on Absorption-Type Company Split of Generic Drugs and Part of the Long-Listed Products BusinessPDF
June 22 Topics Corporate Governance ReportPDF
June 21 Topics Notice of Resolution of the 10th Ordinary General Meeting of Shareholders
⇒Results of the Exercise of Voting Rights(June 22, 2017)
June 20 Release Fingolimod Hydrochloride wins Patent Infringement Lawsuit in the U.S. District CourtPDF
June 1 Release Mitsubishi Tanabe Pharma contribute funding to Global Health Innovative Technology Fund’s second phase ―Targeting treatments for infectious diseases that burden the developing world―PDF
May 23 Topics Notice of Convocation of the 10th Ordinary General Meeting of Shareholders
May 18 Release Approval for partial change in administration / dosage for Crohn’s disease for REMICADE for I.V. Infusion 100, an anti-human TNFα monoclonal antibodyPDF
May 16 Release Mitsubishi Tanabe Pharma announces The Lancet Neurology publication of the positive clinical results of Edaravone for ALSPDF
May 11 Topics IR Meeting for FY2016 Business Results[Material][Video]
May 10 Release Differences Between Non-Consolidated Actual Results for FY2015 and FY2016PDF
May 10 Release Announcement of Financial Results for FY2016
⇒R&D Pipeline "State of New Product Development"
May 10 Release Notice of Dividend of Retained EarningsPDF
May 10 Release Notice Regarding Revision of Business Structure for Recombinant Human Serum Albumin PreparationPDF
May 9 Release Establishment of Vaccine Manufacturing Joint Venture: BIKEN CO.,Ltd.PDF
May 8 Release New Japan-originated ALS treatment option available to patients in the U.S. ―U.S. FDA approves RADICAVA (edaravone) for the treatment of ALSPDF
April 26 Release Introduction of Performance-Linked Stock Compensation Plan for Board DirectorsPDF
April 24 Release Mitsubishi Tanabe Pharma Group receives import and marketing permission in Taiwan for CANAGLU Tablets 100mg, a treatment agent for type 2 diabetes mellitusPDF
March 30 Release Notice regarding approval of indication of ulcerative colitis and additional formulation for SIMPONI subcutaneous injection 50mg syringe (generic name: golimumab), a human monoclonal antibody specific for human TNF αPDF
March 29 Release Mitsubishi Tanabe Pharma and Daiichi Sankyo to Expand Strategic Alliance in the Diabetes Field The companies enter into a marketing alliance agreement for MT-2412, a combination drug for the treatment of type 2 diabetes mellitus, following co-operation for TENELIA Tablets, a selective DPP-4 inhibitor, and CANAGLU Tablets, an SGLT2 inhibitorPDF
March 28 Release Split off and transfer of Generic Drugs and Part of Long-Listed Products Business and Change of SubsidiaryPDF
February 6 Release Announcement of FY2016 3rd Quarter Financial Results
⇒R&D Pipeline "State of New Product Development"
February 6 Topics IR Meeting for FY2016 3rd Quarter Business Results[Material][Audio]
February 3 Release Mitsubishi Tanabe Pharma Corporation Strategically Strengthens Its Foundation in the Field of Inflammatory Bowel Disease Mitsubishi Tanabe Pharma signs co-promotion agreement with Janssen Pharmaceutical K.K. for STELARA for an indication of Crohn’s diseasePDF
January 27 Release Biogen and Mitsubishi Tanabe Pharma Terminate the License Agreement on MT-1303PDF
  • FTSE4Good
  • FTSE Blossom Japan
  • MSCI日本株女性活躍指数
  • MSCIジャパンESGセレクトリーダーズ指数
  • JPX-NIKKEI 400

Investor Relations

Share Price Information

ReadSpeaker docReader makes documents accessible to all users including users with vision problems letting users view and listen to texts.
User guide